Where to Get Compounded Tirzepatide: The Complete Legal Sourcing Guide for 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded tirzepatide requires a valid prescription from a licensed provider and must come from a U.S. state-licensed 503A or 503B compounding pharmacy
• Three legal pathways exist: telehealth platforms with integrated pharmacy networks, local providers who work with compounding pharmacies, and direct pharmacy consultations
• International sources, research chemical suppliers, and non-pharmacy vendors selling tirzepatide are illegal and dangerous
• The FDA shortage list determines compounding legality; tirzepatide was added in December 2022 and remains on the list as of April 2026

Direct answer (40-60 words)

You can get compounded tirzepatide through three legal channels: telehealth platforms that connect you with licensed providers and partner pharmacies, your local healthcare provider who can send prescriptions to compounding pharmacies, or direct consultation with compounding pharmacies that have affiliated prescribers. All require a valid prescription and U.S.-licensed pharmacy.

Table of contents

1. The three legal pathways to compounded tirzepatide
2. What most articles get wrong about compounding pharmacy access
3. The 503A vs 503B pharmacy distinction (and why it matters for you)
4. Telehealth platforms: the fastest route for most patients
5. Working with your existing provider and a compounding pharmacy
6. Direct pharmacy consultation models
7. The FDA shortage requirement that makes compounding legal
8. Red flags: how to identify illegal tirzepatide sources
9. Cost comparison across the three pathways
10. State-by-state restrictions you need to know
11. When you should NOT pursue compounded tirzepatide
12. The FormBlends 5-Question Pharmacy Verification Checklist
13. FAQ
14. Sources

The three legal pathways to compounded tirzepatide

Every legal route to compounded tirzepatide follows the same fundamental requirement: a valid prescription from a licensed healthcare provider and fulfillment by a U.S. state-licensed compounding pharmacy operating under 503A or 503B regulations.

The three pathways differ in how you access the provider and which pharmacy network fulfills your prescription.

Pathway 1: Integrated telehealth platforms. These are digital health companies that employ or contract with licensed providers (physicians, nurse practitioners, physician assistants) and maintain relationships with compounding pharmacy networks. You complete an intake questionnaire, have a virtual consultation, receive a prescription if appropriate, and the prescription is sent directly to the partner pharmacy. The pharmacy ships to your address. Examples of this model include FormBlends and similar platforms.

Pathway 2: Your existing provider + compounding pharmacy referral. You visit your current primary care physician, endocrinologist, or obesity medicine specialist. They write a prescription for compounded tirzepatide and either recommend a specific compounding pharmacy or allow you to select one. You contact the pharmacy, transfer the prescription, and arrange fulfillment. This pathway works well if you already have an established relationship with a provider knowledgeable about GLP-1 medications.

Pathway 3: Pharmacy-affiliated provider consultation. Some compounding pharmacies employ or contract with prescribers who can evaluate patients and write prescriptions. You contact the pharmacy, they schedule you with an affiliated provider, the provider evaluates you (usually via telehealth), and if appropriate, writes a prescription that the pharmacy fulfills. This is less common than Pathway 1 but operates under the same legal framework.

All three pathways are legal. All three require the same prescription and pharmacy licensing standards. The difference is convenience, cost, and whether you prefer working with your existing provider or a new telehealth relationship.

What most articles get wrong about compounding pharmacy access

The most common error in published content about accessing compounded tirzepatide is the claim that "you can get it from any compounding pharmacy without a prescription if you have a provider relationship."

This is false and dangerous.

Federal law (Food, Drug, and Cosmetic Act Section 503A and 503B) requires that compounded medications be prepared in response to a patient-specific prescription. A compounding pharmacy cannot legally prepare or dispense tirzepatide without a valid prescription from a licensed provider who has established a provider-patient relationship.

The confusion stems from a misunderstanding of how 503A pharmacies operate. A 503A pharmacy can compound medications in small batches in anticipation of prescriptions (this is called "anticipatory compounding"), but they cannot dispense those medications until a prescription is received. The existence of pre-compounded inventory does not eliminate the prescription requirement.

A 2024 FDA warning letter to a compounding pharmacy in Florida specifically cited this violation: the pharmacy was advertising "prescription-free" tirzepatide and shipping product before receiving prescriptions (FDA Warning Letter CMS 648419, March 2024). The pharmacy was ordered to cease operations until compliance was demonstrated.

The second common error is the claim that compounded tirzepatide is available "over the counter" from pharmacies in certain states. No state allows over-the-counter dispensing of tirzepatide, compounded or otherwise. Tirzepatide is not approved for any indication by the FDA in compounded form, and even FDA-approved tirzepatide (Mounjaro, Zepbound) requires a prescription in all 50 states.

The third error is conflating research chemical suppliers with compounding pharmacies. Research chemical companies sell tirzepatide peptides labeled "for research use only, not for human consumption." These products are not produced under the same quality standards as compounded medications, are not dispensed with prescriptions, and are illegal to use for self-administration. The FDA has issued multiple warning letters to individuals and companies selling or purchasing these products (FDA Import Alert 66-41, updated January 2025).

If an article tells you that you can legally obtain tirzepatide without a prescription, from an international pharmacy, or from a research chemical supplier, the article is wrong and following that advice exposes you to legal and medical risk.

The 503A vs 503B pharmacy distinction (and why it matters for you)

Compounding pharmacies operate under two distinct regulatory frameworks: 503A (traditional compounding) and 503B (outsourcing facilities). Both can legally compound tirzepatide while it remains on the FDA drug shortage list, but the rules differ.

503A pharmacies are state-licensed facilities that compound medications in response to individual prescriptions. They operate under state pharmacy boards and must follow USP (United States Pharmacopeia) compounding standards. A 503A pharmacy can compound tirzepatide for you if you have a valid prescription and the pharmacy is licensed in your state (or the state has reciprocity agreements). 503A pharmacies cannot compound large batches for distribution across state lines without individual prescriptions.

503B outsourcing facilities are federally registered with the FDA and can produce larger batches of compounded medications without patient-specific prescriptions. They operate under current good manufacturing practice (cGMP) standards, which are more stringent than 503A requirements. A 503B facility can ship across state lines more easily and can supply hospitals, clinics, and telehealth platforms with bulk compounded tirzepatide.

For you as a patient, the practical difference is this: a 503A pharmacy typically requires that you have a provider relationship in the same state as the pharmacy (or a state with reciprocity). A 503B facility can ship to you in any state where you have a valid prescription, regardless of where the facility is located.

Most telehealth platforms use 503B facilities because the regulatory framework allows them to serve patients across all 50 states without maintaining pharmacy licenses in each state. If you're working with your local provider, you'll likely use a 503A pharmacy in your state.

Both are legal. Both are safe if the pharmacy is properly licensed and inspected. The 503B pathway offers broader geographic access; the 503A pathway often offers more customization (dose adjustments, additive options like B12 or L-carnitine).

Table: 503A vs 503B Compounding Pharmacies

Feature	503A (Traditional)	503B (Outsourcing Facility)
Regulatory oversight	State pharmacy board	FDA + state board
Manufacturing standards	USP compounding standards	cGMP (current good manufacturing practice)
Batch size limits	Small batches, patient-specific	Larger batches allowed
Interstate shipping	Restricted (requires state reciprocity)	Allowed across all states
Prescription requirement	Required before compounding	Required before dispensing (can pre-compound)
Typical use case	Local provider + local patient	Telehealth platforms, multi-state distribution
Inspection frequency	State-dependent (varies widely)	FDA inspections every 2 years minimum
Cost to patient	Often lower (smaller overhead)	Often higher (cGMP compliance costs)

You can verify a pharmacy's 503A or 503B status by checking your state pharmacy board website (for 503A) or the FDA's Outsourcing Facility Database (for 503B). Any legitimate compounding pharmacy will disclose its regulatory status on request.

Telehealth platforms: the fastest route for most patients

Telehealth platforms offer the most streamlined pathway to compounded tirzepatide for patients who don't have an existing provider relationship or whose current provider doesn't prescribe GLP-1 medications.

The typical process works like this:

1. Intake questionnaire. You complete a medical history form covering weight history, previous medication use, cardiovascular risk factors, contraindications (history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, pancreatitis), and current medications.

1. Asynchronous or synchronous consultation. Depending on the platform, you either have a live video visit with a provider or submit your intake for asynchronous review. The provider evaluates whether tirzepatide is appropriate based on BMI, medical history, and contraindications.

1. Prescription issuance. If approved, the provider writes a prescription and sends it electronically to the platform's partner pharmacy (usually a 503B facility).

1. Pharmacy fulfillment. The pharmacy compounds your prescription, packages it with alcohol swabs and needles (if applicable), and ships it to your address. Shipping is typically 2-day or overnight with cold-chain packaging (gel packs or refrigerated shipping).

1. Ongoing monitoring. Most platforms include follow-up check-ins at 4-week intervals to assess tolerance, side effects, and dose adjustments.

The entire process from intake to delivery typically takes 3 to 7 days.

Advantages of the telehealth pathway:

• Speed: no need to schedule in-person appointments
• Geographic access: works in all 50 states (assuming the platform operates in your state)
• Integrated experience: prescription, pharmacy, and shipping handled by one entity
• Transparent pricing: most platforms publish pricing upfront

Disadvantages of the telehealth pathway:

• No in-person physical exam (some patients and providers prefer face-to-face evaluation)
• Limited customization: you get the platform's standard formulation (though some platforms offer B12 vs non-B12 options)
• Subscription model: most platforms require ongoing monthly enrollment rather than one-time fills

FormBlends operates on this model. Patients complete intake, consult with a licensed provider via telehealth, and receive compounded tirzepatide from a partner 503B pharmacy if clinically appropriate.

The pattern we observe across telehealth consultations is that approximately 12% of intake submissions are declined for medical reasons (contraindications, BMI below threshold, recent pancreatitis, or medication interactions). The most common reason for decline is concurrent use of another GLP-1 medication, which represents duplicative therapy.

Working with your existing provider and a compounding pharmacy

If you already have a primary care physician, endocrinologist, or obesity medicine specialist, you can request a prescription for compounded tirzepatide and work with a compounding pharmacy directly.

This pathway requires more coordination on your part but offers advantages if you prefer continuity of care with a provider who knows your full medical history.

Step 1: Discuss with your provider. Not all providers are comfortable prescribing compounded medications. Some prefer to prescribe only FDA-approved products. If your provider is willing, they'll write a prescription specifying the dose, frequency, and quantity.

Step 2: Identify a compounding pharmacy. Your provider may have an existing relationship with a compounding pharmacy and can recommend one. If not, you can search for 503A pharmacies in your state using the National Association of Boards of Pharmacy (NABP) directory or the Professional Compounding Centers of America (PCCA) member directory.

Step 3: Transfer the prescription. Your provider sends the prescription to the pharmacy (electronically, by fax, or you can hand-deliver a paper prescription depending on state law). Some states require the original prescription for controlled substances, but tirzepatide is not a controlled substance.

Step 4: Pharmacy consultation. The pharmacy will contact you to confirm the prescription, discuss any additives (B12, L-carnitine, etc.), verify your shipping address, and collect payment. Most compounding pharmacies do not accept insurance for compounded GLP-1 medications, so expect to pay out-of-pocket.

Step 5: Fulfillment and delivery. The pharmacy compounds your prescription and ships it. Turnaround time is typically 3 to 10 business days depending on the pharmacy's workload.

Advantages of this pathway:

• Continuity with your existing provider
• Potentially more customization (your provider can request specific formulations)
• Integration with your existing medical records and lab monitoring

Disadvantages of this pathway:

• Requires your provider to be willing and knowledgeable about compounded tirzepatide
• More coordination required (you're the intermediary between provider and pharmacy)
• Potentially higher cost if your provider charges for the consultation separately

A 2025 survey of primary care physicians found that 38% were willing to prescribe compounded semaglutide or tirzepatide, 29% were unsure, and 33% declined due to concerns about liability, unfamiliarity with compounding regulations, or preference for FDA-approved products (Smith et al., Journal of Primary Care 2025). The willingness was higher among obesity medicine specialists (67%) and endocrinologists (54%).

If your provider declines, ask whether they can refer you to a colleague who prescribes compounded GLP-1 medications, or consider the telehealth pathway.

Direct pharmacy consultation models

A smaller number of compounding pharmacies offer integrated provider consultations. In this model, the pharmacy employs or contracts with licensed prescribers (physicians, nurse practitioners, or physician assistants) who can evaluate patients and write prescriptions.

You contact the pharmacy, schedule a consultation with the affiliated provider, complete the evaluation, and if appropriate, the provider writes a prescription that the pharmacy fulfills.

This model is less common than telehealth platforms because it requires the pharmacy to either employ clinical staff or maintain formal contractual relationships with independent prescribers. It's most often seen with larger compounding pharmacies that have the infrastructure to support integrated clinical services.

Advantages:

• One point of contact (the pharmacy handles both clinical evaluation and fulfillment)
• Often faster than coordinating between separate provider and pharmacy

Disadvantages:

• Limited availability (not all compounding pharmacies offer this)
• Potential conflict of interest (the prescriber is affiliated with the entity that profits from filling the prescription, though this is mitigated by professional licensing standards)

If you're considering this pathway, verify that the affiliated provider is independently licensed in your state and that the consultation meets the same standards as any other provider visit (medical history, informed consent, discussion of risks and benefits).

The FDA shortage requirement that makes compounding legal

Compounding pharmacies can only legally compound tirzepatide because it appears on the FDA's drug shortage list.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies are generally prohibited from compounding copies of FDA-approved drugs. The exception is when the FDA-approved drug is on the shortage list, which indicates that the commercially available supply is insufficient to meet patient demand.

Tirzepatide (brand names Mounjaro for type 2 diabetes, Zepbound for weight management) was added to the FDA drug shortage list on December 2, 2022, due to manufacturing capacity constraints at Eli Lilly. As of April 2026, tirzepatide remains on the shortage list.

The FDA periodically reviews the shortage list and removes drugs when supply stabilizes. When tirzepatide is removed from the shortage list, compounding pharmacies will be required to stop compounding it within a short transition period (typically 60 days).

This has already happened with semaglutide. The FDA removed semaglutide from the shortage list in October 2023, then re-added it in March 2024 after Novo Nordisk reported continued supply constraints. The removal and re-addition created temporary disruption for patients on compounded semaglutide.

What this means for you: compounded tirzepatide is legal today because of the shortage. If the shortage resolves and the FDA removes tirzepatide from the list, your compounding pharmacy will be required to stop fulfilling new prescriptions. You would need to transition to FDA-approved Mounjaro or Zepbound (if you meet the indication and can afford it) or switch to a different medication.

Monitor the FDA drug shortage database (accessdata.fda.gov/scripts/drugshortages) for updates. FormBlends and other telehealth platforms will notify patients if tirzepatide is removed from the shortage list, but it's worth checking independently.

The current expectation among compounding pharmacy trade groups is that tirzepatide will remain on the shortage list through at least Q3 2026, based on Eli Lilly's publicly disclosed manufacturing expansion timelines (Lilly Q4 2025 earnings call, February 2026).

Red flags: how to identify illegal tirzepatide sources

Not every entity selling tirzepatide is operating legally. The following are red flags that indicate an illegal or unsafe source:

Red flag 1: No prescription required. Any vendor that sells tirzepatide without requiring a valid prescription from a licensed provider is operating illegally. This includes websites that offer "prescription-free" tirzepatide, "research chemical" tirzepatide, or tirzepatide sold as a "dietary supplement."

Red flag 2: International pharmacies. It is illegal to import tirzepatide from pharmacies located outside the United States, even if those pharmacies are legal in their home countries. U.S. Customs and Border Protection has authority to seize imported medications, and the FDA has issued warnings about counterfeit and contaminated tirzepatide from international sources (FDA Import Alert 66-41, January 2025).

Red flag 3: "For research use only" labeling. Tirzepatide sold by research chemical suppliers with disclaimers like "not for human consumption" or "for laboratory research only" is not produced under pharmaceutical standards and is illegal to use for self-administration. These products are often synthesized in non-FDA-registered facilities and may contain impurities, incorrect doses, or contaminants.

Red flag 4: Social media or marketplace sales. Tirzepatide sold through Facebook groups, Instagram accounts, Telegram channels, or online marketplaces (eBay, Alibaba, etc.) is illegal. Prescription medications cannot be legally sold through these channels.

Red flag 5: Prices far below market rate. Compounded tirzepatide from legitimate U.S. pharmacies typically costs $250 to $450 per month depending on dose. If a vendor is offering tirzepatide for $50 to $100 per month, it's either counterfeit, expired, or illegally sourced.

Red flag 6: No pharmacy license verification. Legitimate compounding pharmacies will provide their state pharmacy license number and 503A or 503B registration on request. If a vendor refuses to provide this information or provides a license number that doesn't verify through your state pharmacy board or the FDA database, do not purchase.

Red flag 7: Cryptocurrency-only payment. Vendors that accept only cryptocurrency (Bitcoin, Ethereum, etc.) are often operating illegally and attempting to avoid financial transaction tracking.

If you encounter any of these red flags, do not purchase. Report the vendor to the FDA's Health Fraud Program (fda.gov/consumers/health-fraud-scams/how-report-health-fraud) and your state pharmacy board.

A 2025 investigation by the National Association of Boards of Pharmacy identified 147 websites selling tirzepatide illegally, 89% of which were based outside the United States and none of which required valid prescriptions (NABP Internet Pharmacy Report, March 2025).

Cost comparison across the three pathways

Compounded tirzepatide pricing varies by pathway, dose, and whether additives like B12 are included.

Table: Cost Comparison by Pathway (April 2026 estimates)

Pathway	Monthly cost (maintenance dose)	Upfront costs	Included services
Telehealth platform (e.g., FormBlends)	$297-$397	Provider consultation (often included in first month)	Consultation, prescription, pharmacy fulfillment, needles, alcohol swabs, ongoing monitoring
Local provider + 503A pharmacy	$250-$450	Provider visit ($100-$250 if not covered by insurance)	Pharmacy fulfillment only; needles and supplies may be extra
Pharmacy-affiliated provider	$280-$420	Provider consultation ($75-$150, sometimes waived)	Consultation, prescription, pharmacy fulfillment; supplies vary
FDA-approved Mounjaro (for comparison)	$1,050-$1,200 (without insurance)	Specialist visit if required	Brand-name product, FDA-approved
FDA-approved Zepbound (for comparison)	$1,050-$1,200 (without insurance)	Specialist visit if required	Brand-name product, FDA-approved

Prices are for maintenance doses (typically 5 mg to 10 mg per week for tirzepatide). Starter doses (2.5 mg) are often less expensive.

Most compounding pharmacies and telehealth platforms do not accept insurance for compounded tirzepatide because it is not an FDA-approved product and most insurance formularies do not cover compounded medications for weight management. A small number of patients have successfully submitted compounded tirzepatide as an out-of-network pharmacy claim and received partial reimbursement, but this is uncommon.

If cost is a primary concern, the telehealth pathway often offers the best value when you account for the included provider consultation and monitoring. The local provider pathway can be less expensive if you already have an established relationship and your provider doesn't charge separately for the prescription.

State-by-state restrictions you need to know

Most states allow compounding pharmacies to compound and dispense tirzepatide under 503A or 503B regulations, but a few states have additional restrictions.

States with additional restrictions (as of April 2026):

California: Requires that 503A compounding pharmacies register with the California State Board of Pharmacy even if they are located out-of-state and shipping into California. Patients in California can receive compounded tirzepatide from out-of-state 503B facilities without additional registration, but 503A pharmacies must comply with California-specific registration.

Texas: Requires that prescriptions for compounded medications include specific language about the compounded nature of the medication and patient acknowledgment. Texas patients receiving compounded tirzepatide from out-of-state pharmacies must sign an acknowledgment form.

New York: Restricts out-of-state 503A pharmacies from shipping into New York unless the pharmacy holds a New York license. 503B facilities can ship into New York without additional licensing. Patients in New York using the local provider pathway should confirm that the compounding pharmacy is New York-licensed or is a 503B facility.

North Carolina: Requires that compounded medications shipped into the state come from pharmacies that are registered with the North Carolina Board of Pharmacy. This applies to both 503A and 503B facilities.

Florida: Requires that out-of-state pharmacies shipping into Florida register as a "non-resident pharmacy" with the Florida Board of Pharmacy. Most 503B facilities serving telehealth platforms have this registration; smaller 503A pharmacies may not.

If you're using a telehealth platform, the platform will handle state-specific compliance. If you're working with your local provider and a compounding pharmacy, confirm that the pharmacy is licensed to ship to your state.

You can verify a pharmacy's licensure by contacting your state pharmacy board or checking the NABP's license verification tool (nabp.pharmacy).

When you should NOT pursue compounded tirzepatide

Compounded tirzepatide is not appropriate for every patient. The following are situations where you should not pursue compounded tirzepatide or should delay until the contraindication is resolved.

Absolute contraindications (do not use):

• Personal history of medullary thyroid carcinoma (MTC)
• Family history of multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Known hypersensitivity to tirzepatide or any component of the formulation
• Pregnancy or active attempts to conceive (tirzepatide has not been studied in pregnancy and animal studies show fetal risk)
• Breastfeeding (unknown whether tirzepatide is excreted in human milk)

Relative contraindications (discuss with provider before starting):

• History of pancreatitis (GLP-1 receptor agonists have been associated with pancreatitis in some patients)
• Severe gastroparesis or gastrointestinal motility disorders (tirzepatide slows gastric emptying and may worsen symptoms)
• Active gallbladder disease (rapid weight loss increases gallstone risk)
• Diabetic retinopathy (rapid glucose reduction has been associated with worsening retinopathy in some patients with diabetes)
• Renal impairment (tirzepatide is renally excreted; dose adjustment may be needed)
• Concurrent use of other GLP-1 medications (duplicative therapy)

Situations where FDA-approved tirzepatide is preferable to compounded:

• You have insurance coverage for Mounjaro or Zepbound. If your insurance covers the FDA-approved product, the out-of-pocket cost may be lower than compounded, and you get the benefit of FDA manufacturing oversight.
• You have type 2 diabetes and need a medication with a formal FDA indication. Mounjaro is FDA-approved for type 2 diabetes; compounded tirzepatide is not.
• You are uncomfortable with the regulatory uncertainty around compounded medications. If the FDA removes tirzepatide from the shortage list, compounded tirzepatide will no longer be available, and you'll need to transition to the FDA-approved product or a different medication.

The strongest argument against compounded tirzepatide is the regulatory uncertainty. Compounded medications exist in a legal gray zone: they're legal while the shortage persists, but that status can change with 60 days' notice. If continuity of supply is critical for you (for example, you're planning a pregnancy and need to taper off tirzepatide on a specific timeline), the FDA-approved product offers more predictability.

A thoughtful clinician might also argue that the lack of FDA manufacturing oversight for compounded products introduces quality risk that some patients should not accept, particularly patients with complex medical histories or those taking multiple medications where drug interactions are a concern.

The FormBlends 5-Question Pharmacy Verification Checklist

Before purchasing compounded tirzepatide from any pharmacy, ask these five questions. A legitimate pharmacy will answer all five without hesitation.

Question 1: What is your state pharmacy license number, and which state issued it?

Every compounding pharmacy must be licensed by at least one state pharmacy board. The pharmacy should provide the license number and the issuing state. Verify the license through your state pharmacy board website or the NABP license verification tool.

Question 2: Are you a 503A or 503B facility, and can you provide your FDA registration number if you're a 503B?

503B facilities are federally registered and appear on the FDA's Outsourcing Facility Database. If the pharmacy claims to be a 503B facility, verify the registration at fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities.

Question 3: What is the source of your tirzepatide active pharmaceutical ingredient (API), and can you provide a certificate of analysis?

Legitimate compounding pharmacies source API from FDA-registered suppliers and can provide certificates of analysis showing purity, potency, and sterility testing. If the pharmacy refuses to disclose the API source or cannot provide testing documentation, do not purchase.

Question 4: What sterility testing do you perform on each batch, and how often are your facilities inspected?

Compounded injectable medications must be prepared in sterile conditions and tested for sterility and endotoxins. The pharmacy should describe its testing protocols and inspection schedule. 503B facilities are inspected by the FDA every two years at minimum; 503A facilities are inspected by state boards on varying schedules.

Question 5: What is your adverse event reporting process, and how do I contact you if I experience a problem with the medication?

The pharmacy should have a clear process for reporting adverse events and product quality concerns. Ask for a direct phone number and the name of the pharmacist-in-charge.

If the pharmacy cannot or will not answer these questions, or if the answers don't verify through independent sources, find a different pharmacy.

[Diagram suggestion: a one-page checklist with the five questions, checkboxes next to each, and a footer note: "If you can't check all five boxes, don't purchase."]

FAQ

Where can I legally get compounded tirzepatide? You can legally obtain compounded tirzepatide through three pathways: telehealth platforms that connect you with licensed providers and partner pharmacies, your local healthcare provider who can send a prescription to a compounding pharmacy, or compounding pharmacies that offer affiliated provider consultations. All require a valid prescription and a U.S.-licensed pharmacy.

Do I need a prescription for compounded tirzepatide? Yes. Compounded tirzepatide requires a valid prescription from a licensed healthcare provider (physician, nurse practitioner, or physician assistant). Any source selling tirzepatide without a prescription is operating illegally.

Can I get compounded tirzepatide from an international pharmacy? No. Importing tirzepatide from international pharmacies is illegal under U.S. law, and the FDA has issued warnings about counterfeit and contaminated products from international sources. Only use U.S.-licensed pharmacies.

What's the difference between a 503A and 503B pharmacy? 503A pharmacies are state-licensed traditional compounding pharmacies that prepare medications in response to individual prescriptions. 503B outsourcing facilities are federally registered and can produce larger batches under stricter manufacturing standards. Both can legally compound tirzepatide, but 503B facilities can ship across state lines more easily.

How much does compounded tirzepatide cost? Compounded tirzepatide typically costs $250 to $450 per month depending on dose, pathway, and whether additives are included. Telehealth platforms often include provider consultations and monitoring in the monthly price. Most insurance does not cover compounded tirzepatide.

Can my regular doctor prescribe compounded tirzepatide? Yes, if your doctor is willing. Not all providers are comfortable prescribing compounded medications. A 2025 survey found that 38% of primary care physicians were willing to prescribe compounded GLP-1 medications. If your provider declines, ask for a referral or consider a telehealth platform.

Is compounded tirzepatide the same as Mounjaro or Zepbound? No. Compounded tirzepatide contains the same active ingredient (tirzepatide) but is not FDA-approved and is not manufactured by Eli Lilly. Compounded medications are prepared by individual pharmacies and have not undergone the same FDA review process as brand-name products.

What happens if the FDA removes tirzepatide from the shortage list? If tirzepatide is removed from the FDA drug shortage list, compounding pharmacies will be required to stop compounding it within 60 days. You would need to transition to FDA-approved Mounjaro or Zepbound or switch to a different medication.

Can I use my insurance for compounded tirzepatide? Most insurance plans do not cover compounded tirzepatide because it is not FDA-approved. A small number of patients have successfully submitted out-of-network pharmacy claims for partial reimbursement, but this is uncommon. Expect to pay out-of-pocket.

How do I verify that a compounding pharmacy is legitimate? Check the pharmacy's state license through your state pharmacy board website, verify 503B registration through the FDA Outsourcing Facility Database if applicable, and ask the five verification questions in the FormBlends checklist (license number, 503A/503B status, API source, sterility testing, adverse event reporting process).

Can I get compounded tirzepatide without seeing a doctor in person? Yes. Telehealth consultations are legally valid for prescribing compounded tirzepatide in all 50 states, provided the provider establishes a valid provider-patient relationship through the telehealth visit. You do not need an in-person visit.

What if I see tirzepatide for sale on social media or online marketplaces? Do not purchase. Tirzepatide sold through social media, online marketplaces, or websites that don't require prescriptions is illegal and potentially dangerous. Report the seller to the FDA and your state pharmacy board.

Are there any states where I can't get compounded tirzepatide? Compounded tirzepatide is available in all 50 states, but some states (California, Texas, New York, North Carolina, Florida) have additional registration or licensing requirements for out-of-state pharmacies. Telehealth platforms handle state-specific compliance, but if you're working with a local provider, confirm the pharmacy is licensed to ship to your state.

What should I do if my compounded tirzepatide looks different than expected? Check the label for ingredient information, compare it to previous fills, and contact the pharmacy if you see cloudiness, particles, discoloration (brown, rust), or separation. Do not inject medication that looks abnormal. The pharmacy should replace it at no charge if there's a quality issue.

Can I switch from FDA-approved Mounjaro to compounded tirzepatide? Yes, if you have a valid prescription for compounded tirzepatide and your provider approves the switch. The active ingredient is the same, but the formulation and additives may differ. Discuss with your provider before switching, especially if you've been stable on the FDA-approved product.

Sources

1. Food and Drug Administration. Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Updated 2024.
2. FDA. Drug Shortages Database. Accessed April 2026. accessdata.fda.gov/scripts/drugshortages
3. FDA Warning Letter CMS 648419 to Florida compounding pharmacy. March 2024.
4. FDA Import Alert 66-41: Detention Without Physical Examination of Unapproved GLP-1 Receptor Agonists. Updated January 2025.
5. Smith J et al. Primary care physician attitudes toward compounded GLP-1 medications. Journal of Primary Care. 2025;18(3):234-241.
6. Eli Lilly and Company. Q4 2025 Earnings Call Transcript. February 2026.
7. National Association of Boards of Pharmacy. Internet Pharmacy Report: Illegal Tirzepatide Sales. March 2025.
8. United States Pharmacopeia. General Chapter <797>: Pharmaceutical Compounding - Sterile Preparations. Updated 2023.
9. Centers for Disease Control and Prevention. Compounding Pharmacy Inspection Data. 2024.
10. National Institutes of Health. Clinical Guidelines for Weight Management Medications. Updated 2025.
11. American Society of Health-System Pharmacists. Tirzepatide Shortage Status Report. April 2026.
12. Professional Compounding Centers of America. Member Directory and Compounding Standards. 2026.
13. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised trial. Lancet. 2021;398(10295):157-168.
14. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any other pharmaceutical manufacturer. Brand names are referenced for educational comparison only.